Our findings indicate that ezrin is an important modulator of chemotherapy resistance in breast cancer and that anti-ezrin therapy can sensitize metastatic breast cancer cells to DOX or DTX in preclinical models of neoadjuvant or neoadjuvant plus adjuvant treatment. This evidence concerns the gene EZR and breast carcinoma.